PRESS RELEASE 2024

Ferring bolsters global gene therapy supply chain with European manufacturing facility

By celia in PRESS RELEASE 2024 on 03 October 2024

Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study

By celia in PRESS RELEASE 2024 on 01 October 2024

Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in…

Dr. Michael Rosenblatt joins Ferring Pharmaceuticals’ Board of Directors

By celia in PRESS RELEASE 2024 on 23 July 2024

Ferring Pharmaceuticals successfully launches its third Swiss Franc Bond offering for CHF 330 million

By celia in PRESS RELEASE 2024 on 27 May 2024

Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals successfully launches…

Ferring announces results demonstrating the efficacy and safety of follitropin delta for women undergoing in vitro fertilisation using an agonist protocol

By celia in PRESS RELEASE 2024 on 17 May 2024

Ferring announces results demonstrating the efficacy and safety of follitropin delta for…

Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal

By celia in PRESS RELEASE 2024 on 18 April 2024

Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal…

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

By celia in PRESS RELEASE 2024 on 09 April 2024

Launch of two first-in-class medicines in 2023 marks start of exciting phase…

Ferring announces full availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.

By celia in PRESS RELEASE 2024 on 16 January 2024